Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Table 5 Base case results

	EINSTEIN DVT			EINSTEIN PE
	Rivaroxaban	Dual LMWH/VKA therapy	Incremental	Rivaroxaban	Dual LMWH/VKA therapy	Incremental
Patients appropriate for 3 months of anticoagulation
Drug acquisition cost (£)	220	98	122	217	99	118
Other costs (£)	1592	1964	−372	4295	4808	−513
Total costs (£)	1812	2063	−251	4511	4907	−396
QALYs	13.286	13.264	0.022	11.940	11.912	0.027
ICER (£)			Rivaroxaban dominates			Rivaroxaban dominates
Patients appropriate for 6 months of anticoagulation
Drug acquisition cost (£)	398	104	295	393	105	288
Other costs (£)	1561	2040	−479	4153	4654	−501
Total costs (£)	1959	2143	−184	4546	4759	−213
QALYs	13.294	13.268	0.026	11.992	11.979	0.013
ICER (£)			Rivaroxaban dominates			Rivaroxaban dominates
Patients appropriate for 12 months of anticoagulation
Drug acquisition cost (£)	731	114	617	728	115	613
Other costs (£)	1512	2186	−673	4154	4900	−746
Total costs (£)	2243	2299	−56	4881	5015	−133
QALYs	13.308	13.274	0.034	12.035	12.015	0.020
ICER (£)			Rivaroxaban dominates			Rivaroxaban dominates
Patients appropriate for lifelong anticoagulation
Drug acquisition cost (£)	6566	288	6278	6025	284	5740
Other costs (£)	2084	6835	−4751	4532	9209	−4677
Total costs (£)	8649	7122	1527	10,557	9493	1064
QALYs	13.507	13.331	0.176	12.526	12.375	0.150
ICER (£)			8677			7072

ICER, incremental cost-effectiveness ratio; LMWH, low molecular weight heparin; QALY, quality-adjusted life-year; VKA, vitamin K antagonist.

ISSN: 1477-9560